Salute e Benessere
Navamedic ASA: Double digit growth in the 3rd quarter, 2025
The acquisition of the dne pharma business was completed in July, with a subsequent successful rights issue completed in October.
"We are excited about the acquisition of the dne pharma business. The portfolio of products we have acquired fits well into the Navamedic setup and provides a new focus area with growth potential, Addiction, within our Rx portfolio. Further to this, addiction is a growing societal challenge and Navamedic is now in a position to be at the forefront of treatment within this category," said Kathrine Gamborg Andreassen , CEO of Navamedic.
Operating costs ended at NOK 40.8 million , compared to NOK 37.1 million last year. Operating results (EBIT) for the second quarter of 2025 amounted to negative NOK 0.2 million , mostly due to the amortization of the intangible assets acquired through the dne transaction. Net financial items ended at negative NOK 3.6 million and profit before tax was negative NOK 3.8 million . The total cash flow for the quarter was positive NOK 9.1 million and the cash balance at the end of the quarter was NOK 51.7 million .
Navamedic continues to see growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company.
"The third quarter was marked by the acquisition of the dne business and growth across our three business areas. The acquired portfolio of products with growth potential within the addiction treatment area, combined with the antibiotics portfolio, the Parkinsons disease product Flexilev in Orafid and Navamedic's other hero brands, sets Navamedic up for growth going forward towards the ambition of reaching NOK 1 billion in revenues," Andreassen concluded.
Navamedic will present the results for the third quarter of 2025 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo . It will be webcast at the following link:
https://navamedic.com/investors/financial-results/
Kathrine Gamborg Andreassen , CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/navamedic-asa/r/navamedic-asa--double-digit-growth-in-the-3rd-quarter--2025,c4257501
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/navamedic-asa-double-digit-growth-in-the-3rd-quarter-2025-302596271.html